Last reviewed · How we verify
KN060 Low
KN060 Low is a monoclonal antibody targeting PD-L1.
KN060 Low is a monoclonal antibody targeting PD-L1. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | KN060 Low |
|---|---|
| Sponsor | Suzhou Alphamab Co., Ltd. |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by blocking the PD-L1 protein, which is involved in the immune system's regulation. This allows the immune system to attack cancer cells more effectively.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KN060 Low CI brief — competitive landscape report
- KN060 Low updates RSS · CI watch RSS
- Suzhou Alphamab Co., Ltd. portfolio CI